AK-ALASKA-CARGO
25.1.2021 06:03:09 CET | Business Wire | Press release
Alaska Cargo and Cold Storage, LLC (ACCS) and the State of Alaska executed a 55-year lease agreement at Ted Stevens Anchorage International Airport (ANC), marking a major milestone in the development of a more than 700,000-square-foot, climate-controlled warehouse facility. With 32.5 million cubic feet of capacity, the facility will provide ANC with a critical piece of infrastructure at the world’s sixth-busiest cargo airport.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210124005094/en/
“This project will improve shipping to and through Anchorage, create jobs, and show the world that Alaska is open for business,” said Alaska Gov. Mike Dunleavy. “We’re excited about the potential this integral piece of the global cold chain has to make Ted Stevens Anchorage International Airport and Alaska a more attractive place for global companies to do business.”
ACCS is a joint venture of industrialist Chad Brownstein and McKinley Capital Management, LLC (McKinley Capital), which is led by Rob Gillam. Brownstein is the founder of Rocky Mountain Resources which has aggregated an industrial complex throughout the Mountain West. Gillam is the chief executive officer and chief investment officer at McKinley Capital.
Located on the Great Circle Route, ANC is within 9.5 hours of 90% of key markets in Asia, Europe and North America. Illustrating this importance, during COVID-19 air travel disruptions, ANC was the busiest airport in the world on select days in 2020. Historically, a limited supply of warehouse and transfer facilities at ANC designates ANC’s air cargo support as “gas-and-go.” Brownstein and Gillam say the development of ACCS — located runway-adjacent and within a Foreign Trade Zone — will position ANC to be transformed into a key cold chain transfer hub for global air cargo carriers.
“We believe Alaska offers world-class development and investment opportunities,” said Gillam. “ACCS is a clear instance. There are many industries that require cold storage. One example is Alaska seafood, one of Alaska’s biggest exports, and it’s shipped globally. For decades, almost no value-added or fresh production occurred in-state. ACCS will lead the way in changing that trend. Now, Alaska can capitalize on its valuable position as a hub between North America and Asia. We see this project as something with potential to increase air cargo traffic and spur local economic development. We’re confident ACCS will ultimately bring more dollars and jobs into Anchorage and across the state.”
“The addition of this facility with cold storage capabilities brings new opportunity for the global distribution tenants and customers already benefitting from the unique features of the Anchorage trade and tariff exemptions,” said Brownstein. “The facility will serve as the cold storage gateway between the Americas, Asia, and Europe, and further integrate Alaska into the global cold chain.”
“Cargo carriers and their industry partners are recognizing the advantages of operating at ANC. ACCS’s new facility will strengthen our already powerful cargo network,” said Airport Director Jim Szczesniak. “ANC offers daily, nonstop freighter service to more than 30 destinations and near daily service to an additional 20. This facility will allow perishables to be consolidated from North America and Latin America and then distributed to freighters bringing perishables closer to the consumer. Cutting the time from field or sea to the consumer will provide a better product.”
In September 2020, the U.S. Department of Transportation awarded the Alaska Energy Authority (AEA), a $21 million BUILD grant to administer in support of the ACCS project.
“It’s incredible to be a part of this project that has the potential to improve Alaska’s position on the global supply chain,” said AEA Executive Director Curtis W. Thayer. “Our partnership with the ACCS team enables AEA to deploy its expertise to assure that the best of cutting-edge technology will make the building a showpiece in energy-efficiency.”
The facility will be constructed in phases. The first phase will be roughly 190,000 square feet with plans to begin construction in the second half of 2021. When fully completed, the facility will offer cold and warm storage, quick cargo, and general warehousing options, logistics services, and auxiliary space for tenant offices.
About Alaska Cargo and Cold Storage, LLC
Alaska Cargo and Cold Storage, LLC (ACCS) is a joint venture of industrialist Chad Brownstein and McKinley Capital Management, LLC (McKinley Capital), which is led by Rob Gillam. Brownstein is the founder of Rocky Mountain Resources which has aggregated an industrial complex throughout the Mountain West. Gillam is the chief executive officer and chief investment officer at McKinley Capital. ACCS signed a 55-year ground lease with the State of Alaska to develop a secure, more than 700,000-square-foot and 32.5 million-cubic-foot, climate-controlled warehouse facility at Ted Stevens Anchorage International Airport (ANC).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210124005094/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
